Preventing chronic kidney disease in special populations

American Journal of Hypertension

Volumn 18, Issue 4 SUPPL., 2005, Pages 106-111

  Jamerson, Kenneth A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chronic kidney disease; Diabetes; Diabetic nephropathy; End stage renal disease; Hypertension; Isolated systolic hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; METOPROLOL; RAMIPRIL; THIAZIDE DIURETIC AGENT;

AFRICAN AMERICAN; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE SEVERITY; ETHNOLOGY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYSTOLIC HYPERTENSION;

EID: 17444426123     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.11.018     Document Type: Conference Paper

References (44)

1. M.J. Lysaght Maintenance dialysis population dynamics current trends and long-term implications J Am Soc Nephrol 13 2002 S37 S40
2. U.S. Renal Data System USRDS 2003 Annual Data Report Atlas of End-Stage Renal Disease in the United States 2003 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
3. P. Jungers, J. Zingraff, B. Page, G. Albouze, T. Hannedouche, N.K. Man Detrimental effects of late referral in patients with chronic renal failure a case-control study Kidney Int Suppl 41 1993 S170 S173
4. National Kidney Foundation: NKF Kidney Disease Outcomes Quality Initiative. Available at: http://www.kidney.org/professionals/doqi/kdoqi/ p2_background.htm. Accessed May 14, 2004.
5. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification Am J Kidney Dis 39 Suppl 1 2002 S1 S266
6. G.L. Bakris, M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, R. Toto, K. Tuttle, J. Douglas, W. Hsueh, J. Sowers Preserving renal function in adults with hypertension and diabetes a consensus approach Am J Kidney Dis 36 2000 646 661
7. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr, E.J. Roccella National High Blood Pressure Education Program Coordinating Committee the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report JAMA 289 2003 2560 2572
8. American Diabetes Association Hypertension management in adults with diabetes Diabetes Care 27 Suppl 1 2004 S65 S67
9. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 Suppl 1 2004 S1 S290
10. J. Coresh, G.L. Wei, G. McQuillan, F.L. Brancati, A.S. Levey, C. Jones, M.J. Klag Prevalence of high blood pressure and elevated serum creatinine level in the United States findings from the third National Health and Nutrition Examination Survey (1988-1994) Arch Intern Med 161 2001 1207 1216
11. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, L.L. Hamm, P.A. McCullough, B.L. Kasiske, E. Kelepouris, M.J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D.J. Spinosa, P.W. Wilson American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Kidney disease as a risk factor for development of cardiovascular disease Circulation 108 2003 2154 2169
12. M.J. Klag, P.K. Whelton, B.L. Randall, J.D. Neaton, F.L. Brancati, J. Stamler End-stage renal disease in African-American and white men 16-year MRFIT findings JAMA 277 1997 1293 1298
13. H.L. Hillege, W.M.T. Janssen, A.A.A. Bak, G.F.H. Diercks, D.E. Grobbee, H.J.G.M. Crijns, W.H. Van Gilst, D. De Zeeuw, P.E. De Jong PREVEND Study Group Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity J Intern Med 249 2001 519 526
14. J.S. Jensen, B. Feldt-Rasmussen, K. Borch-Johnsen, P. Clausen, M. Appleyard, G. Jensen Microalbuminuria and its relation to cardiovascular disease and risk factors a population-based study of 1254 hypertensive individuals J Hum Hypertens 11 1997 727 732
15. W.F. Keane, G. Eknoyan Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE) a position paper of the National Kidney Foundation Am J Kidney Dis 33 1999 1004 1010
16. American Diabetes Association Nephropathy in diabetes Diabetes Care 27 Suppl 1 2004 S79 S83 Available at: http://care.diabetesjournals.org/cgi/content/ full/27/supple-1/S79. Accessed May 14, 2004.
17. M. Cirillo, D. Stellato, M. Laurenzi, W. Panarelli, A. Zanchetti, N.G. De Santo GUBBIO Study Collaborative Research Group Pulse pressure and isolated systolic hypertension association with microalbuminuria Kidney Int 58 2000 1211 1218
18. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 265 1991 3255 3264
19. J.H. Young, M.J. Klag, P. Muntner, J.L. Whyte, M. Pahor, J. Coresh Blood pressure and decline in kidney function findings from the Systolic Hypertension in the Elderly Program (SHEP) J Am Soc Nephrol 13 2002 2776 2782
20. L.F. Fried, M.G. Shlipak, C. Crump, A.J. Bleyer, J.S. Gottdiener, R.A. Kronmal, L.H. Kuller, A.B. Newman Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals J Am Coll Cardiol 41 2003 1364 1372
21. L.V. Franse, M. Pahor, M. Di Bari, G.W. Somes, W.C. Cushman, W.B. Applegate Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program Hypertension 35 2000 1025 1030
22. J.A. Staessen, R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, W.H. Birkenhäger, C.J. Bulpitt, P.W. de Leeuw, C.T. Dollery, A.E. Fletcher, F. Forette, G. Leonetti, C. Nachev, E.T. O'Brien, J. Rosenfeld, J.L. Rodicio, J. Tuomilehto, A. Zanchetti Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension Lancet 350 1997 757 764
23. L.M. Ruilope Renoprotection and renin-angiotensin system blockade in diabetes mellitus Am J Hypertens 10 1997 325S 331S
24. American Diabetes Association Screening for type 2 diabetes Diabetes Care 27 Suppl 1 2004 S11 S14
25. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 BMJ 317 1998 703 713
26. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
27. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, I. Raz Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
28. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.-H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
29. H.-H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
30. R.O. Estacio, B.W. Jeffers, W.R. Hiatt, S.L. Biggerstaff, N. Gifford, R.W. Schrier The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 338 1998 645 652
31. P. Tatti, M. Pahor, R.P. Byington, P. Di Mauro, R. Guarisco, G. Strollo, F. Strollo Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 1998 597 603
32. L.H. Lindholm, L. Hansson, T. Ekbom, B. Dahlöf, J. Lanke, E. Linjer, B. Schersten, P.O. Wester, T. Hedner, U. de Faire STOP Hypertension-2 Study Group Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients results from the Swedish Trial in Old Patients with Hypertension-2 J Hypertens 18 2000 1671 1675
33. R. Fogari, P. Preti, A. Zoppi, A. Rinaldi, L. Corradi, C. Pasotti, L. Poletti, G.L. Marasi, G. Derosa, A. Mugellini, C. Voglini, P. Lazzari Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients Am J Hypertens 15 2002 1042 1049
34. G.S. Chrysant, S.G. Chrysant Has the role of calcium channel blockers in treating hypertension finally been defined? Curr Hypertens Rep 4 2003 295 300
35. National Center for Health Statistics Vital Statistics System: Available at: http://webapp.cdc.gov/sasweb/ncipc/leadcaus10.html. Accessed May 11, 2004.
36. M.E. Andrew, D.W. Jones, M.R. Wofford, S.B. Wyatt, P.J. Schreiner, C.A. Brown, D.B. Young, H.A. Taylor Ethnicity and unprovoked hypokalemia in the Atherosclerosis Risk in Communities Study Am J Hypertens 15 2002 594 599
37. K.M. Flegal, M.D. Carroll, C.L. Ogden, C.L. Johnson Prevalence and trends in obesity among US adults, 1999-2000 JAMA 288 2002 1723 1727
38. American Heart Association: Heart disease and stroke statistics - 2004 update. Available at: http://americanheart.org/presenter.jhtml?identifier= 3000090. Accessed May 14, 2004.
39. K.T. Khaw, E. Barrett-Connor Dietary potassium and stroke-associated mortality. A 12-year prospective population study N Engl J Med 316 1987 235 240
40. B.J. Materson Correction Single-drug therapy for hypertension in men N Engl J Med 330 1994 1689
41. J.G. Douglas, G.L. Bakris, M. Epstein, K.C. Ferdinand, C. Ferrario, J.M. Flack, K.A. Jamerson, W.E. Jones, J. Haywood, R. Maxey, E.O. Ofili, E. Saunders, E.L. Schiffrin, D.A. Sica, J.R. Sowers, D.G. Vidt Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Management of high blood pressure in African Americans consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med 163 2003 525 541
42. L.Y. Agodoa, L. Appel, G.L. Bakris, G. Beck, J. Bourgoignie, J.P. Briggs, J. Charleston, D. Cheek, W. Cleveland, J.G. Douglas, M. Douglas, D. Dowie, M. Faulkner, A. Gabriel, J. Gassman, T. Greene, Y. Hall, L. Hebert, L. Hiremath, K. Jamerson, C.J. Johnson, J. Kopple, J. Kusek, J. Lash, J. Lea, J.B. Lewis, M. Lipkowitz, S. Massry, J. Middleton, E.R. Miller III, K. Norris, D. O'Connor, A. Ojo, R.A. Phillips, V. Pogue, M. Rahman, O.S. Randall, S. Rostand, G. Schulman, W. Smith, D. Thornley-Brown, C.C. Tisher, R.D. Toto, J.T. Wright Jr, S. Xu African American Study of Kidney Disease and Hypertension (AASK) Study Group Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis a randomized controlled trial JAMA 285 2001 2719 2728
43. J.T. Wright Jr, G. Bakris, T. Greene, L.Y. Agodoa, L.J. Appel, J. Charleston, D. Cheek, J.G. Douglas-Baltimore, J. Gassman, R. Glassock, L. Hebert, K. Jamerson, J. Lewis, R.A. Phillips, R.D. Toto, J.P. Middleton, S.G. Rostand African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial JAMA 288 2002 2421 2431
44. J.M. Flack, G.L. Bakris, J. McGregor, D. Purkayastha, M. Gatlin, O.M. Nwose Safety and efficacy of combination ACE inhibitor/calcium channel blocker therapy versus ACE inhibitor monotherapy in African American patients with hypertension and type 2 diabetes Am J Hypertens 17 2004 180A [abstract] Abstract P-401